Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTLE
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.1.1 PATENT LANDSCAPE
6.1.2 USPTO NUMBER
6.1.3 EPIO NUMBER
6.1.4 PATENT STRENGTH AND QUALITY
6.1.5 PATENT CLAIMS
6.1.6 PATENT CITATIONS
6.1.7 PATENT LITIGATION AND LICENSING
6.1.8 FILE OF PATENT
6.1.9 PATENT RECEIVED CONTRIES
6.1.10 TECHNOLOGY BACKGROUND
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH SPECIALIST
6.8 OTHER KOL SNAPSHOT
7 EPIDEMIOLOGY
7.1 INCIDENCE OF ALL BY GENDER
7.2 TREATMENT RATE
7.3 MORTALITY RATE
7.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
7.5 PATIENT TREATMENT SUCCESS RATES
8 REGULATORY FRAMEWORK
8.1 REGULATORY APPROVAL PROCESS
8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
8.3 REGULATORY APPROVAL PATHWAYS
8.4 LICENSING AND REGISTRATION
8.5 POST-MARKETING SURVEILLANCE
8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
9 PIPELINE ANALYSIS
9.1 PHASE III CANDIDATES
9.2 PHASE II CANDIDATES
9.3 PHASE I CANDIDATES
9.4 OTHERS (PRE-CLINICAL AND RESEARCH)
10 MARKET ACCESS
10.1 10-YEAR MARKET FORECAST
10.2 CLINICAL TRIAL RECENT UPDATES
10.3 ANNUAL NEW FDA APPROVED DRUGS
10.4 DRUGS MANUFACTURER AND DEALS
10.5 MAJOR DRUG UPTAKE
10.6 CURRENT TREATMENT PRACTICES
10.7 IMPACT OF UPCOMING THERAPY
11 R & D ANALYSIS
11.1 COMPARATIVE ANALYSIS
11.2 DRUG DEVELOPMENTAL LANDSCAPE
11.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
11.4 THERAPEUTIC ASSESSMENT
11.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
11.6 DRUGS AND THERAPIES IN CLINICAL TRIALS
11.7 EMERGING TREATMENT APPROACHES
12 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, BY TYPE
12.1 OVERVIEW
12.2 PAPILLARY UROTHELIAL CARCINOMA
12.3 FLAT UROTHELIAL CARCINOMA
13 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET , BY GRADE TYPE
13.1 OVERVIEW
13.2 LOW-GRADE BLADDER TUMOR
13.3 HIGH-GRADE BLADDER TUMOR
14 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, BY NATURE
14.1 OVERVIEW
14.2 INVASIVE NATURE
14.3 NON INVASIVE NATURE
15 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, BY TREATMENT
15.1 OVERVIEW
15.2 NADOFARAGENE FIRADENOVEC GENE THERAPY
15.3 CHEMOTHERAPY
15.3.1 INTRAVESICAL CHEMOTHERAPY
15.3.1.1. MITOMYCIN-C
15.3.1.2. GEMCITABINE
15.3.1.3. DOCETAXEL
15.3.1.4. VALRUBICIN
15.3.1.5. OTHERS
15.3.2 SYSTEMIC CHEMOTHERAPY
15.3.2.1. 5-FU.
15.3.2.2. CARBOPLATIN.
15.3.2.3. GEMCITABINE.
15.3.2.4. CISPLATIN.
15.3.2.5. PEMETREXED
15.3.2.6. PACLITAXEL.
15.3.2.7. DOXORUBICIN.
15.3.2.8. METHOTREXATE
15.3.2.9. VINBLASTINE
15.3.2.10. OTHERS
15.3.3 OTHERS
15.4 RADIOTHERAPY
15.4.1 EXTERNAL BEAM RADIATION THERAPY (EBRT)
15.4.2 INTERNAL RADIATION THERAPY (BRACHYTHERAPY)
15.5 IMMUNOTHERAPY
15.5.1 LOCAL THERAPY
15.5.1.1. BACILLUS CALMETTE-GUERIN (BCG)
15.5.1.2. INTERFERON
15.5.1.2.1. ROFERON-A
15.5.1.2.2. INTRON A
15.5.1.2.3. ALFERON
15.5.2 SYSTEMIC THERAPY
15.5.2.1. ATEZOLIZUMAB
15.5.2.2. DURVALUMAB
15.5.2.3. AVELUMAB
15.5.2.4. NIVOLUMAB
15.5.2.5. PEMBROLIZUMAB
15.5.2.6. OTHERS
15.6 TARGETED THERAPY
15.6.1 ERDAFITINIB
15.6.2 ENFORTUMAB
15.6.3 RAMUCIRUMAB
15.6.4 SACITUZUMAB GOVITECAN
15.6.5 OTHERS
15.7 SURGERY
15.7.1 TRANSURETHRAL RESECTION OF BLADDER TUMOR (TURBT)
15.7.2 URINARY DIVERSION
15.7.3 CYSTECTOMY
15.7.3.1. PARTIAL CYSTECTOMY
15.7.3.2. RADICAL CYSTECTOMY
15.7.4 OTHERS
16 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, BY DIAGNOSTIC TEST
16.1 OVERVIEW
16.2 BIOPSY
16.3 URETEROSCOPY
16.4 URINE CYTOLOGY
16.5 COMPUTED TOMOGRAPHY SCANNING
16.6 INTRAVENOUS PYELOGRAM (IVP)
16.7 ULTRASOUND IMAGING
16.8 CYSTOSCOPY
16.9 OTHERS
17 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, BY STAGES
17.1 OVERVIEW
17.2 STAGE 0
17.3 STAGE I
17.4 STAGE II
17.5 STAGE III
17.6 STAGE IV
18 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
18.1 OVERVIEW
18.2 ORAL
18.2.1 SOLID
18.2.1.1. PILL
18.2.1.2. CAPSULE
18.2.1.3. TABLETS
18.2.1.4. OTHERS
18.2.2 LIQUID
18.2.3 OTHERS
18.3 PARENTERAL
18.3.1 INTRAVENOUS
18.3.2 SUBCUTANEOUS
18.3.3 OTHERS
18.4 OTHERS
19 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, BY GENDER
19.1 OVERVIEW
19.2 MALE
19.3 FEMALE
20 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, BY END USER
20.1 OVERVIEW
20.2 HOSPITAL
20.2.1 BY TYPE
20.2.1.1. PUBLIC
20.2.1.2. PRIVATE
20.2.2 BY LEVEL
20.2.2.1. LEVEL 1
20.2.2.2. LEVEL 2
20.2.2.3. LEVEL 3
20.3 SPECIALTY CLINICS
20.4 HOME HEALTHCARE
20.5 DIAGNOSTIC CENTERS
20.6 RESEARCH INSTITUTES
20.7 OTHERS
21 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
21.1 OVERVIEW
21.2 DIRECT TENDER
21.3 RETAIL SALES
21.3.1 ONLINE PHARMACY
21.3.2 HOSPITALS PHARMACY
21.4 OTHERS
22 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, COMPANY LANDSCAPE
22.1 COMPANY SHARE ANALYSIS: GLOBAL
22.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
22.3 COMPANY SHARE ANALYSIS: EUROPE
22.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
22.5 MERGERS & ACQUISITIONS
22.6 NEW PRODUCT DEVELOPMENT & APPROVALS
22.7 EXPANSIONS
22.8 REGULATORY CHANGES
22.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
23 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, BY REGION
GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
23.1 NORTH AMERICA
23.1.1 U.S.
23.1.2 CANADA
23.1.3 MEXICO
23.2 EUROPE
23.2.1 GERMANY
23.2.2 FRANCE
23.2.3 U.K.
23.2.4 ITALY
23.2.5 SPAIN
23.2.6 RUSSIA
23.2.7 TURKEY
23.2.8 BELGIUM
23.2.9 NETHERLANDS
23.2.10 SWITZERLAND
23.2.11 REST OF EUROPE
23.3 ASIA-PACIFIC
23.3.1 JAPAN
23.3.2 CHINA
23.3.3 SOUTH KOREA
23.3.4 INDIA
23.3.5 AUSTRALIA
23.3.6 SINGAPORE
23.3.7 THAILAND
23.3.8 MALAYSIA
23.3.9 INDONESIA
23.3.10 PHILIPPINES
23.3.11 REST OF ASIA-PACIFIC
23.4 SOUTH AMERICA
23.4.1 BRAZIL
23.4.2 ARGENTINA
23.4.3 REST OF SOUTH AMERICA
23.5 MIDDLE EAST AND AFRICA
23.5.1 SOUTH AFRICA
23.5.2 SAUDI ARABIA
23.5.3 UAE
23.5.4 EGYPT
23.5.5 ISRAEL
23.5.6 REST OF MIDDLE EAST AND AFRICA
23.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
24 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, SWOT AND DBMR ANALYSIS
25 GLOBAL UROTHELIAL CARCINOMA TREATMENT MARKET, COMPANY PROFILE
25.1 ASTELLAS PHARMA US, INC. + SEAGEN INC.
25.1.1 COMPANY OVERVIEW
25.1.2 REVENUE ANALYSIS
25.1.3 GEOGRAPHIC PRESENCE
25.1.4 PRODUCT PORTFOLIO
25.1.5 RECENT DEVELOPMENTS
25.2 MERCK SHARP & DOHME LLC
25.2.1 COMPANY OVERVIEW
25.2.2 REVENUE ANALYSIS
25.2.3 GEOGRAPHIC PRESENCE
25.2.4 PRODUCT PORTFOLIO
25.2.5 RECENT DEVELOPMENTS
25.3 JANSSEN BIOTECH, INC. + PHARMACYCLICS LLC (ABBVIE COMPANY)
25.3.1 COMPANY OVERVIEW
25.3.2 REVENUE ANALYSIS
25.3.3 GEOGRAPHIC PRESENCE
25.3.4 PRODUCT PORTFOLIO
25.3.5 RECENT DEVELOPMENTS
25.4 EMD SERONO, INC.
25.4.1 COMPANY OVERVIEW
25.4.2 REVENUE ANALYSIS
25.4.3 GEOGRAPHIC PRESENCE
25.4.4 PRODUCT PORTFOLIO
25.4.5 RECENT DEVELOPMENTS
25.5 GILEAD SCIENCES, INC.
25.5.1 COMPANY OVERVIEW
25.5.2 REVENUE ANALYSIS
25.5.3 GEOGRAPHIC PRESENCE
25.5.4 PRODUCT PORTFOLIO
25.5.5 RECENT DEVELOPMENTS
25.6 GENENTECH, INC. (F. HOFFMANN-LA ROCHE LTD )
25.6.1 COMPANY OVERVIEW
25.6.2 REVENUE ANALYSIS
25.6.3 GEOGRAPHIC PRESENCE
25.6.4 PRODUCT PORTFOLIO
25.6.5 RECENT DEVELOPMENTS
25.7 UROGEN PHARMA, LTD.
25.7.1 COMPANY OVERVIEW
25.7.2 REVENUE ANALYSIS
25.7.3 GEOGRAPHIC PRESENCE
25.7.4 PRODUCT PORTFOLIO
25.7.5 RECENT DEVELOPMENTS
25.8 ACERTA PHARMA BV
25.8.1 COMPANY OVERVIEW
25.8.2 REVENUE ANALYSIS
25.8.3 GEOGRAPHIC PRESENCE
25.8.4 PRODUCT PORTFOLIO
25.8.5 RECENT DEVELOPMENTS
25.9 BRISTOL-MYERS SQUIBB COMPANY
25.9.1 COMPANY OVERVIEW
25.9.2 REVENUE ANALYSIS
25.9.3 GEOGRAPHIC PRESENCE
25.9.4 PRODUCT PORTFOLIO
25.9.5 RECENT DEVELOPMENTS
25.1 GSK PLC.
25.10.1 COMPANY OVERVIEW
25.10.2 REVENUE ANALYSIS
25.10.3 GEOGRAPHIC PRESENCE
25.10.4 PRODUCT PORTFOLIO
25.10.5 RECENT DEVELOPMENTS
25.11 INCYTE BIOSCIENCES DISTRIBUTION B.V.
25.11.1 COMPANY OVERVIEW
25.11.2 REVENUE ANALYSIS
25.11.3 GEOGRAPHIC PRESENCE
25.11.4 PRODUCT PORTFOLIO
25.11.5 RECENT DEVELOPMENTS
25.12 ASTRAZENECA
25.12.1 COMPANY OVERVIEW
25.12.2 REVENUE ANALYSIS
25.12.3 GEOGRAPHIC PRESENCE
25.12.4 PRODUCT PORTFOLIO
25.12.5 RECENT DEVELOPMENTS
25.13 HIKMA PHARMACEUTICALS PLC + JUNSHI BIOSCIENCES
25.13.1 COMPANY OVERVIEW
25.13.2 REVENUE ANALYSIS
25.13.3 GEOGRAPHIC PRESENCE
25.13.4 PRODUCT PORTFOLIO
25.13.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIF IED OR REPLACED ON REQUEST
26 RELATED REPORTS
27 CONCLUSION
28 QUESTIONNAIRE
29 ABOUT DATA BRIDGE MARKET RESEARCH
